Overview

Study of LaNova Medicines(LM)-302 in Patients With Advance Solid Tumors

Status:
Not yet recruiting
Trial end date:
2024-05-05
Target enrollment:
Participant gender:
Summary
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
LaNova Medicines Limited